Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial

OBJECTIVES: Cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX-4) is superior to FOLFOX-4 alone as a first-line treatment for patients with metastatic colorectal cancer with RAS wild-type (RAS wt mCRC), with significantly improved survival benefit by TAILOR, an open-label, randomised, m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huijuan, Huang, Lingfei, Gao, Peng, Zhu, Zhengyi, Ye, Weifeng, Ding, Haiying, Fang, Luo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044820/
https://www.ncbi.nlm.nih.gov/pubmed/32051297
http://dx.doi.org/10.1136/bmjopen-2019-030738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044820/
https://www.ncbi.nlm.nih.gov/pubmed/32051297
http://dx.doi.org/10.1136/bmjopen-2019-030738

Ejemplares similares